These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 19778838

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
    Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA.
    Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 27. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
    Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA.
    Clin Cancer Res; 2013 Mar 01; 19(5):1269-80. PubMed ID: 23300276
    [Abstract] [Full Text] [Related]

  • 28. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R, Pettitt AR, Cano-Soumillac C, Griffin RJ, Cowell IG, Austin CA, Durkacz BW.
    Clin Cancer Res; 2008 Jun 15; 14(12):3984-92. PubMed ID: 18559621
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
    Awan FT, Jones JA, Maddocks K, Poi M, Grever MR, Johnson A, Byrd JC, Andritsos LA.
    Ann Hematol; 2016 Jun 15; 95(7):1137-43. PubMed ID: 27118540
    [Abstract] [Full Text] [Related]

  • 32. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
    Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM.
    Leuk Res; 2013 Oct 15; 37(10):1195-9. PubMed ID: 23867058
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.
    Byrd JC, Rai KR, Sausville EA, Grever MR.
    Semin Oncol; 1998 Feb 15; 25(1):65-74. PubMed ID: 9482528
    [Abstract] [Full Text] [Related]

  • 35. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia.
    Pepper C, Thomas A, Hoy T, Fegan C, Bentley P.
    Br J Haematol; 2001 Jul 15; 114(1):70-7. PubMed ID: 11472347
    [Abstract] [Full Text] [Related]

  • 36. New agents in chronic lymphocytic leukemia.
    Lin TS.
    Curr Hematol Malig Rep; 2010 Jan 15; 5(1):29-34. PubMed ID: 20425394
    [Abstract] [Full Text] [Related]

  • 37. Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.
    Grever MR, Lucas DM, Johnson AJ, Byrd JC.
    Best Pract Res Clin Haematol; 2007 Sep 15; 20(3):545-56. PubMed ID: 17707839
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.